摘要
目的探讨TACE治疗原发性肝癌(HCC)伴门脉癌栓(PVTT)患者的潜在预后因子。方法对2010年1月至2016年3月间临床资料完整、HCC伴PVTT接受TACE治疗的患者46例进行回顾性分析,建立病例资料数据库,对相关因素采用Kaplan-Meier检验进行生存率的单因素分析,COX风险比例模型进行多因素分析,筛选出独立预后因子。应用寿命表法计算生存期。结果 46例患者6、12、18和24个月的生存率分别为51.2%、28.9%、23.4%和10.2%,中位生存时间为6.7个月。根据m RECIST标准完全缓解者1例(2.1%),部分缓解者11例(23.9%),稳定者16例(34.8%),进展者18例(39.2%)。在多因素分析中,影响患者的独立预后因子为局部肿瘤反应、腹水、胆碱酯酶、动静脉瘘。结论影响HCC患者生存时间的独立预后因子为局部肿瘤反应、腹水、胆碱酯酶、动静脉瘘。
Objective To investigate the potential prognostic factors in patients with hepatocellular carcinoma（HCC） complicate by portal vein tumor thrombosis（PVTT） who are treated with transcatheter arterial chemoembolization（TACE）. Methods The complete clinical data of a total of 46 patients with HCC complicate by PVTT, who were treated with TACE during the period from January 2010 to March 2016, were retrospectively analyzed. Clinical material database was established. Kaplan-Meier test was adopted to analyze the survival rate and the COX risk ratio model was used to screen out the independent prognostic factors. Life table method was employed to calculate the survival time. Results The 6-, 12-, 18-and 24-month survival rates were 51.2%, 28.9%, 23.4% and 10.2%, respectively. The median survival time was 6.7 months.According to m RECIST standard, complete remission（CR） was obtained in one patient（2.1%）, partial remission（PR） in 11 patients（23.9%）, stable disease（SD） in 16 patients（34.8%） and progress disease（PD） in 18 patients（39.2%）. Multivariate analysis indicated that local tumor response, ascites, cholinesterase,and arteriovenous fistula were the independent factors affecting the prognosis. Conclusion The independent prognostic factors that affect the survival time of HCC patient include local tumor response, ascites,cholinesterase and arteriovenous fistula.
出处
《介入放射学杂志》
CSCD
北大核心
2018年第3期266-271,共6页
Journal of Interventional Radiology
关键词
原发性肝细胞癌
门静脉癌栓
肝动脉化疗栓塞
预后因子
生存率
primary hepatocelluar carcinoma
portal vein tumor thrombosis
transcatheter arterial chemoembolization
prognostic factor
survival rate
